Wolfe Research analyst Andy Chen downgraded Alpine Immune Sciences (ALPN) to Peer Perform from Outperform after the announcement that the company agreed to an acquisition by Vertex (VRTX). In light of the announced deal, the firm expects “limited fluctuations in price” of Alpine shares until the acquisition is complete, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN: